Abstract
The pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, was examined in healthy male volunteers after the oral administration of a single dose of 100, 200, 400, or 600 mg and multiple doses of 300 mg twice daily for 6.5 days (13 total doses). Throughout the whole study period, AM-1155 was well tolerated in every subject. In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively. The elimination half-life was 7 to 8 h, independently of the doses. The unchanged drug was excreted mainly in the urine, with 82 to 88% of the doses appearing for 72 h. The fecal recovery of the unchanged drug amounted to 5.7% for 72 h after a single oral administration of a 400-mg dose. Urinary excretion of metabolites was minimal. The serum protein binding was 20%, independently of the concentrations in serum. The concentrations in saliva were approximately 80% of those in serum. The intake of food had no effect on the pharmacokinetic parameters and urinary excretion of AM-1155 except the slight decrease in area under the concentration-time curve. The concurrent administration of probenecid prolonged the elimination half-life, increased the area under the concentration-time curve, and decreased the apparent total body clearance, renal clearance, urinary recovery of unchanged drug, and the excretion ratio (intrinsic renal clearance of AM-1155/creatinine clearance). This indicated that the tubular secretion contributed to the renal excretion of AM-1155. In the multiple-dose study, the concentrations of AM-1155 in serum and urine reached a steady state within 2 to 3 days. The measured concentrations in serum fitted well the simulation curve, which reflected the persistence of linear pharmacokinetics of AM-1155. In conclusion, AM-1155 is expected to be clinically useful because of its potent antibacterial activity and favorable pharmacokinetics.
Full Text
The Full Text of this article is available as a PDF (247.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Granneman G. R., Carpentier P., Morrison P. J., Pernet A. G. Pharmacokinetics of temafloxacin in humans after single oral doses. Antimicrob Agents Chemother. 1991 Mar;35(3):436–441. doi: 10.1128/aac.35.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hosaka M., Yasue T., Fukuda H., Tomizawa H., Aoyama H., Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother. 1992 Oct;36(10):2108–2117. doi: 10.1128/aac.36.10.2108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kusajima H., Ooie T., Kawahara F., Uchida H. High-performance liquid chromatographic determination of 6,8-difluoro-1-(2-fluoroethyl)-1,4- dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and its metabolites in laboratory animals. J Chromatogr. 1986 Aug 22;381(1):137–148. doi: 10.1016/s0378-4347(00)83572-0. [DOI] [PubMed] [Google Scholar]
- Nakashima M., Kanamaru M., Uematsu T., Takiguchi A., Mizuno A., Itaya T., Kawahara F., Ooie T., Saito S., Uchida H. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):133–144. doi: 10.1093/jac/22.supplement_d.133. [DOI] [PubMed] [Google Scholar]
- Shiba K., Saito A., Shimada J., Hori S., Kaji M., Miyahara T., Kusajima H., Kaneko S., Saito S., Ooie T. Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob Agents Chemother. 1990 Jan;34(1):58–64. doi: 10.1128/aac.34.1.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shimada J., Yamaji T., Ueda Y., Uchida H., Kusajima H., Irikura T. Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob Agents Chemother. 1983 Jan;23(1):1–7. doi: 10.1128/aac.23.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stone J. W., Andrews J. M., Ashby J. P., Griggs D., Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother. 1988 Oct;32(10):1508–1510. doi: 10.1128/aac.32.10.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sörgel F., Jaehde U., Naber K., Stephan U. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet. 1989;16 (Suppl 1):5–24. doi: 10.2165/00003088-198900161-00004. [DOI] [PubMed] [Google Scholar]
- Thorsteinsson S. B., Bergan T., Oddsdottir S., Rohwedder R., Holm R. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy. 1986;32(5):408–417. doi: 10.1159/000238444. [DOI] [PubMed] [Google Scholar]
- Tomioka H., Saito H., Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother. 1993 Jun;37(6):1259–1263. doi: 10.1128/aac.37.6.1259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Uematsu T., Nakashima M. Pharmacokinetic aspects of newer quinolones. Prog Drug Res. 1992;38:39–55. [PubMed] [Google Scholar]
- Wakabayashi E., Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother. 1994 Mar;38(3):594–601. doi: 10.1128/aac.38.3.594. [DOI] [PMC free article] [PubMed] [Google Scholar]